Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nutritional Status in Locally Advanced or Metastatic Solid Cancer Patients in Spain: the NutriOncoSearch (NOS) Study (NOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04168814
Recruitment Status : Not yet recruiting
First Posted : November 19, 2019
Last Update Posted : November 27, 2019
Sponsor:
Collaborators:
Baxter Healthcare Corporation
Iqvia Pty Ltd
Information provided by (Responsible Party):
JULIO CESAR DE LA TORRE MONTERO, Universidad Pontificia Comillas

Brief Summary:

Malnutrition is a common medical problem in oncology patients. It is well known that the presence of malnutrition negatively affects patients' evolution and their quality of life, increasing the incidence of infection, hospital stay, and mortality.

The new knowledge of cancer biology has made it possible to know the mechanisms of cancer progression.

New treatments have been developed thanks to this knowledge including molecular target treatments aimed at these cancer mechanics and to reverse the antitumor capacity of the immune system. However, these treatments have different toxicities than classic and anachronistic treatments such as chemotherapy and radiotherapy, including alterations in glucose metabolism, endocrinopathies, rhabdomyolysis, etc. that can alter both the patient's nutritional status and quality of life. Additionally, a deficient nutritional status can have an impact on the intestinal microbiota, compromising the efficacy of the new antitumor treatments.

The principal objective of this study is to characterize the nutritional status of the cancer outpatient receiving either immunotherapies or any other targeted therapies through a screening performed in Hospital consultations in Spain.

Secondary Endpoints are (a). To describe the percentage of patients that receive nutritional counseling or nutritional support (enteral and/or parenteral nutrition) among those diagnosed as malnourished or at risk. And (b) to categorize the percentage and descriptive characteristics of cancer patients with mild, moderate or severe malnutrition that goes to a hospital consultation in Spain and describe the percentage and descriptive characteristics of patients with malnutrition according to sociodemographic and clinical characteristics.


Condition or disease Intervention/treatment
Malnutrition Oncologic Complications Oncology Quality of Life Other: Observational test

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 593 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: An Observational Study of the Nutritional Status in Locally Advanced or Metastatic Solid Cancer Patients While Receiving Immunotherapy and New Targeted Therapies in Spain: the NutriOncoSearch (NOS) Study
Estimated Study Start Date : February 10, 2020
Estimated Primary Completion Date : March 15, 2020
Estimated Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malnutrition

Group/Cohort Intervention/treatment
Oncology patients
  1. Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).
  2. Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: Tyrosine kinase inhibitors, Pi3K-akt-mTOR inhibitors, inhibitors of kinase-dependent cyclins (CDK-i), PARP inhibitors, and other inhibitors of transcription pathways MEK, EFGR. At least six month of treatment.
Other: Observational test
Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site.




Primary Outcome Measures :
  1. Nutritional status [ Time Frame: Two months ]
    To characterize the nutritional status of the cancer outpatient receiving either immunotherapies or any other targeted therapies through a screening performed in Hospital consultations in Spain.


Secondary Outcome Measures :
  1. Nutritional counselling [ Time Frame: Two months ]
    To describe the percentage of patients that receive nutritional counselling or nutritional support (enteral and/or parenteral nutrition) among those diagnosed as malnourished or at risk.

  2. Descriptive characteristic mild, moderate or severe malnutrition [ Time Frame: Two months ]
    To categorize the percentage and descriptive characteristic of cancer patients with mild, moderate or severe malnutrition that goes to a hospital consultation in Spain and describe the percentage and descriptive characteristic of patients with malnutrition according to sociodemographic and clinical characteristics (type of tumor and TNM stage).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population

Total number of subjects to be enrolled: 593 subjects.

  • Number of study or comparison groups: one. This is an observational study.
  • The study will be performed in multiple different days: the recruitment will be concomitant and limited to a minimum of 40 and a maximum of 70 patients depending on the number of patients the center deals with. The estimation is that each center will dedicate from one to two weeks to recruit the total number of patients.
Criteria

Inclusion Criteria:

  1. Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).
  2. Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: Tyrosine kinase inhibitors, Pi3K-akt-mTOR inhibitors, inhibitors of kinase-dependent cyclins (CDK-i), PARP inhibitors, and other inhibitors of transcription pathways MEK, EFGR. At least six month of treatment.

Key Exclusion Criteria:

  1. Estimated survival below 12 weeks (palliative criteria).
  2. Patients that meet diagnostic criteria (DSM-IV and ICD-10) of nervous anorexia and bulimia.
  3. Patients with severe psychiatric disorders.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04168814


Contacts
Layout table for location contacts
Contact: JULIO c DE LA TORRE-MONTERO, Ph.D +34678581021 juliodelatorre@comillas.edu
Contact: NIEVES GIL GÓMEZ, MSN +34666931914 nievesgilgomez@gmail.com

Locations
Layout table for location information
Spain
Universidad Pontificia Comillas
Madrid, Spain, 28015
Contact: Julio C. de la Torre-Montero, Ph.D    +34 678581021    juliodelatorre@comillas.edu   
Contact: ANA S. FERNANDES-RIBEIRO, Ph.D    +34678581021    asfribeiro@comillas.edu   
Sponsors and Collaborators
Universidad Pontificia Comillas
Baxter Healthcare Corporation
Iqvia Pty Ltd
Investigators
Layout table for investigator information
Principal Investigator: JULIO C. DE LA TORRE-MONTERO, Ph.D Hospital Vall d´Hebron

Additional Information:
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: JULIO CESAR DE LA TORRE MONTERO, Principal Investigator, lecturer, research coordinator., Universidad Pontificia Comillas
ClinicalTrials.gov Identifier: NCT04168814    
Other Study ID Numbers: SEEO-19-01-NOS
First Posted: November 19, 2019    Key Record Dates
Last Update Posted: November 27, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by JULIO CESAR DE LA TORRE MONTERO, Universidad Pontificia Comillas:
Nutritional status
Oncology Patients
Anticancer treatments
Quality of Life
Additional relevant MeSH terms:
Layout table for MeSH terms
Malnutrition
Neoplasms
Nutrition Disorders